Pancreatic Cancer Research

ResearcherUniversity of FoggiaNo recent work listed

Octavio Caba

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3426-8294; OpenAlex author ID A5026264004. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
2
Collaborators
19
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper

Papers 11

  1. Serum biomarkers for the differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.4251/wjgo.v15.i2.268↗
  2. Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. Last author DOI 10.3748/wjg.v27.i39.6515↗
  3. Liquid biopsy approach to pancreatic cancer. Last author DOI 10.4251/wjgo.v13.i10.1263↗
  4. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Last author DOI 10.3390/cancers12041002↗
  5. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. Co-author DOI 10.1371/journal.pone.0194844↗
  6. Proteomic biomarkers in body fluids associated with pancreatic cancer. Last author DOI 10.18632/oncotarget.24654↗
  7. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study. Co-author DOI 10.1177/1087057116671490↗
  8. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.taap.2016.10.003↗
  9. Current Status of Immunotherapy Treatments for Pancreatic Cancer. Last author DOI 10.1097/mcg.0000000000000623↗
  10. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. Co-author DOI 10.1007/s10620-014-3291-3↗
  11. Serum cytokine profile in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000155↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cristina Jiménez‐Luna · 9 shared papers, 2014–2023 · strength 0.88
  2. Joaquina Martínez-Galán · 5 shared papers, 2018–2023 · strength 0.80
  3. Jose Carlos Prados · 9 shared papers, 2014–2021 · strength 0.68
  4. Carolina Torres · 7 shared papers, 2014–2021 · strength 0.51
  5. Consolación Melguizo · 5 shared papers, 2014–2020 · strength 0.37
  6. Sonia Perales · 3 shared papers, 2014–2021 · strength 0.22
  7. Antonio Irigoyen · 4 shared papers, 2014–2018 · strength 0.20
  8. Raúl Ortíz · 3 shared papers, 2014–2018 · strength 0.19
  9. José Pérez del Palacio · 2 shared papers, 2017–2020 · strength 0.18
  10. Jose Manuel Sanchez-Manas · 1 shared paper, 2021 · strength 0.15
  11. Manuel Benavides · 2 shared papers, 2016–2018 · strength 0.13
  12. Javier Gallego-Plazas · 2 shared papers, 2016–2018 · strength 0.13
  13. Carmen Guillén‐Ponce · 2 shared papers, 2016–2018 · strength 0.13
  14. Enrique Aranda · 2 shared papers, 2016–2018 · strength 0.13
  15. Ariadna Martín-Blázquez · 1 shared paper, 2020 · strength 0.11
  16. Francisca Vicente · 1 shared paper, 2020 · strength 0.11
  17. Antonia Aránega · 2 shared papers, 2014 · strength 0.07
  18. Ana Linares · 2 shared papers, 2014 · strength 0.07
  19. Sandra Ríos Peces · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.